Search tips
Search criteria 


Logo of envhperEnvironmental Health PerspectivesBrowse ArticlesAbout EHPGeneral InformationAuthorsMediaProgramsPartnerships
Environ Health Perspect. 1987 November; 75: 53–57.
PMCID: PMC1474447
Research Article

Possible neurologic effects of aspartame, a widely used food additive.


The artificial sweetener aspartame (L-aspartyl-L-phenylalanyl-methyl ester), is consumed, primarily in beverages, by a very large number of Americans, causing significant elevations in plasma and, probably, brain phenylalanine levels. Anecdotal reports suggest that some people suffer neurologic or behavioral reactions in association with aspartame consumption. Since phenylalanine can be neurotoxic and can affect the synthesis of inhibitory monoamine neurotransmitters, the phenylalanine in aspartame could conceiveably mediate neurologic effects. If mice are given aspartame in doses that elevate plasma phenylalanine levels more than those of tyrosine (which probably occurs after any aspartame dose in humans), the frequency of seizures following the administration of an epileptogenic drug, pentylenetetrazole, is enhanced. This effect is simulated by equimolar phenylalanine and blocked by concurrent administration of valine, which blocks phenylalanine's entry into the brain. Aspartame also potentiates the induction of seizures by inhaled fluorothyl or by electroconvulsive shock. Perhaps regulations concerning the sale of food additives should be modified to require the reporting of adverse reactions and the continuing conduct of mandated safety research.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.0M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Wurtman RJ, Maher TJ. Strategies for assessing the effects of food additives on the brain and behavior. Fundam Appl Toxicol. 1984 Jun;4(3 Pt 2):S318–S322. [PubMed]
  • Bradstock MK, Serdula MK, Marks JS, Barnard RJ, Crane NT, Remington PL, Trowbridge FL. Evaluation of reactions to food additives: the aspartame experience. Am J Clin Nutr. 1986 Mar;43(3):464–469. [PubMed]
  • Johns DR. Migraine provoked by aspartame. N Engl J Med. 1986 Aug 14;315(7):456–456. [PubMed]
  • Ferguson JM. Interaction of aspartame and carbohydrates in an eating-disordered patient. Am J Psychiatry. 1985 Feb;142(2):271–271. [PubMed]
  • Drake ME. Panic attacks and excessive aspartame ingestion. Lancet. 1986 Sep 13;2(8507):631–631. [PubMed]
  • Wurtman RJ. Aspartame: possible effect on seizure susceptibility. Lancet. 1985 Nov 9;2(8463):1060–1060. [PubMed]
  • Walton RG. Seizure and mania after high intake of aspartame. Psychosomatics. 1986 Mar;27(3):218–220. [PubMed]
  • Stegink LD, Filer LJ, Jr, Baker GL. Effect of aspartame and aspartate loading upon plasma and erythrocyte free amino acid levels in normal adult volunteers. J Nutr. 1977 Oct;107(10):1837–1845. [PubMed]
  • Fernstrom JD, Fernstrom MH, Gillis MA. Acute effects of aspartame on large neutral amino acids and monoamines in rat brain. Life Sci. 1983 Apr 4;32(14):1651–1658. [PubMed]
  • Ranney RE, Oppermann JA, Muldoon E, McMahon FG. Comparative metabolism of aspartame in experimental animals and humans. J Toxicol Environ Health. 1976 Nov;2(2):441–451. [PubMed]
  • Fernstrom JD, Wurtman RJ, Hammarstrom-Wiklund B, Rand WM, Munro HN, Davidson CS. Diurnal variations in plasma concentrations of tryptophan, tryosine, and other neutral amino acids: effect of dietary protein intake. Am J Clin Nutr. 1979 Sep;32(9):1912–1922. [PubMed]
  • Maher TJ, Glaeser BS, Wurtman RJ. Diurnal variations in plasma concentrations of basic and neutral amino acids and in red cell concentrations of aspartate and glutamate: effects of dietary protein intake. Am J Clin Nutr. 1984 May;39(5):722–729. [PubMed]
  • Stegink LD, Filer LJ, Jr, Baker GL, McDonnell JE. Effect of an abuse dose of aspartame upon plasma and erythrocyte levels of amino acids in phenylketonuric heterozygous and normal adults. J Nutr. 1980 Nov;110(11):2216–2224. [PubMed]
  • Fernstrom JD, Faller DV. Neutral amino acids in the brain: changes in response to food ingestion. J Neurochem. 1978 Jun;30(6):1531–1538. [PubMed]
  • Elwyn DH, Parikh HC, Shoemaker WC. Amino acid movements between gut, liver, and periphery in unanesthetized dogs. Am J Physiol. 1968 Nov;215(5):1260–1275. [PubMed]
  • Oldendorf WH. Brain uptake of radiolabeled amino acids, amines, and hexoses after arterial injection. Am J Physiol. 1971 Dec;221(6):1629–1639. [PubMed]
  • Levy HL, Waisbren SE. Effects of untreated maternal phenylketonuria and hyperphenylalaninemia on the fetus. N Engl J Med. 1983 Nov 24;309(21):1269–1274. [PubMed]
  • Jobe PC, Dailey JW, Reigel CE. Noradrenergic and serotonergic determinants of seizure susceptibility and severity in genetically epilepsy-prone rats. Life Sci. 1986 Sep 1;39(9):775–782. [PubMed]
  • Milner JD, Irie K, Wurtman RJ. Effects of phenylalanine on the release of endogenous dopamine from rat striatal slices. J Neurochem. 1986 Nov;47(5):1444–1448. [PubMed]

Articles from Environmental Health Perspectives are provided here courtesy of National Institute of Environmental Health Science